by David Brindley | Mar 19, 2013
. Part 5 in Cell Therapy Industry 2027 series A short time ago, I had the immense pleasure of driving through the Napa Valley bathed in a warm pastel sunset. The view was accompanied by a two-chord soundtrack: the reassuring chinking of several bottles of the...
by David Brindley | Dec 18, 2012
Some words have the ability to induce instant and unexplained anxiety. In developing industries, such as cell therapy, one such example is regulation – of any sort. Crudely, our negative perception of regulation can be attributed to two factors: an aversion to both...
by Ubaka Ogbogu | May 18, 2012
The Federal Government has proposed amendments to the Assisted Human Reproduction Act, the legislation that governs embryo research, including many aspects of stem cell research. The amendments, which are contained in an omnibus budget implementation bill tabled...
by David Kent | Feb 29, 2012
Last week I attended a breakfast at Eversheds, a law firm in Cambridge entitled Stem cell patenting, Brüstle v Greenpeace: business breaker or business as usual? which focused on the practical implications of the recent decision from the Court of Justice of the...
by Stem Cell Network | Oct 5, 2011
by Drew Lyall The World Stem Cell Summit taking place this week in Pasadena, California, occupies a unique place in the stem cell calendar. The summit brings together patient advocates, policy makers, industry and scientists from around the world to take stock of...
Comments